There are currently 2700 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
NCT05473910
Recruiting
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Mass General Hospital, Boston, Massachusetts
Conditions: AML, Myelodysplastic Syndromes, ALL, Adult
Register for Updates
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
NCT05914766
Recruiting
The aim of this study is to evaluate the feasibility and acceptability of conducting a randomized trial of a brief psychoeducational intervention versus enhanced usual care for patients with locally advanced rectal cancer who are initiating neoadjuvant multimodality treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Rectal Cancer, Self Efficacy
Register for Updates
Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)
NCT06584942
Recruiting
The goal of this study is to observe the impact of suvorexant, sold as BELSOMRA, on brain activity of people who frequently use cannabis. Suvorexant is an FDA-approved medication to treat insomnia. Researchers think that suvorexant may reduce activity in certain parts of the brain associated with cannabis use. Researchers are studying if this medication does affect brain activity in these areas. For this study, participants will be asked to complete four study visits over approximately 14 days.... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/14/2025
Locations: Center for Addiction Medicine, Massachusetts General Hospital, Boston, Massachusetts
Conditions: Cue-reactivity, Cannabis Use Disorder, Functional MRI, Orexin Antagonist
Register for Updates
Integrating Pain-CBT Into an mHealth Analgesic Support Intervention for Patients With Chronic Pain From Advanced Cancers
NCT06722014
Recruiting
Smartphone Technology to Alleviate Malignant Pain (STAMP) + Cognitive Behavioral Therapy for Pain (STAMP+CBT) The purpose of the study is to develop and refine the mHealth pain-CBT app intervention and carry out a randomized pilot to test the novel mHealth (Mobile health technology) intervention, which harmonizes psychological and pharmacological support for advanced cancer pain. The name of the study smartphone application involved in this study is: -STAMP+CBT
Gender:
ALL
Ages:
22 years and above
Trial Updated:
05/14/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Pain, Pain Syndrome, Advanced Cancer
Register for Updates
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
NCT06744296
Recruiting
This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Massachusetts Eye and Ear, Boston, Massachusetts
Conditions: Squamous Cell Carcinoma of Head and Neck
Register for Updates
Systems Biology of Early Atopy
NCT04798079
Recruiting
The goal of this study is to establish a birth cohort that collects prenatal and early life biosamples and environmental samples and rigorously phenotypes young children for food allergy and Atopic Dermatitis (AD) to identify prenatal and early life markers of high risk for food allergy and AD, as well as biological pathways (endotypes) that result in these conditions. Primary Objectives: * To study the role and interrelationships of established and novel clinical, environmental, biological, a... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
05/13/2025
Locations: Massachusetts General Hospital, Translational and Clinical Research Center, Boston, Massachusetts
Conditions: Allergic Diseases, Food Allergy, Atopic Dermatitis
Register for Updates
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
NCT05911763
Recruiting
This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/13/2025
Locations: Massachusetts General Hospital- Site Number : 8400017, Boston, Massachusetts +1 locations
Conditions: Hemophilia A
Register for Updates
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
NCT06369155
Recruiting
This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Uterine Serous Carcinoma, Uterine Carcinoma, Uterine Cancer
Register for Updates
Positive Minds Strong Joints for Knee Osteoarthritis
NCT06493903
Recruiting
The aim of this research study is to test the feasibility of a physical and mental health intervention (Positive Minds, Strong Joints or PMSJ) for Black adults with knee osteoarthritis (OA).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/13/2025
Locations: Boston University, Boston, Massachusetts
Conditions: Osteoarthritis, Knee
Register for Updates
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
NCT06532565
Recruiting
The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of GS-2121 as monotherapy and GS-2121 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recomm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Advanced Solid Tumors
Register for Updates
Telehealth Exercise and Mindfulness for Pain in Osteoarthritis - Stage 1B
NCT06684587
Recruiting
The goal of this randomized controlled trial (RCT) is to test the feasibility of an 10-week telehealth mindful exercise intervention compared to a telehealth exercise only intervention for people with knee osteoarthritis (OA). This RCT will be fully digital with all recruitment, assessments, and intervention being conducted remotely.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/13/2025
Locations: Boston University, Boston, Massachusetts
Conditions: Knee Osteoarthritis
Register for Updates
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963
Recruiting
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer, Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumors
Register for Updates